• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

Bezlotoxumab associated with lower recurrence of C. difficile infection: The MODIFY I and II trials

byMatthew Lin, MD
January 26, 2017
in Gastroenterology, Infectious Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Bezlotoxumab therapy associated with significantly lower rate of recurrent C. difficile infection compared to placebo.

2. Actoxumab not efficacious when administered aloine or in combination with bezlotoxumab in reducing rates of recurrent C. difficile infection.

Evidence Rating Level: 1 (excellent)

Study Rundown: In hospitalized patients, C. difficile is a widespread cause of infectious diarrhea. An emerging approach in preventing the recurrence of C. difficile infection involves co-administering toxin-neutralizing monoclonal antibodies along with standard of care of antibiotics. Actoxumab and bezlotoxumab are human monoclonal antibodies that target C. difficile toxins A and B, respectively. In the Monocolona antibodies for C. Difficile Therapy (MODIFY I and II) Trials, researchers aimed to determine the efficacy of administering both antibodies (with antibiotics) together, separately and against placebo in reducing rates of symptomatic C. difficile recurrence.

They found that bezlotuxumab was associated with a significantly lower rate of recurrent infection compared to placebo, with both having a similar safety profile. Additionally, in subgroup analysis, researchers also demonstrated that for participants categorized as high risk for recurrent infection (i.e. patients >65 years of age, immunocompromised), bezlotuxumab was similarly efficacious compared to placebo in preventing recurrent infection. In contrast, actoxumab failed to provide benefit in prevention C. difficile recurrence. Limitations of the study include lack of standardization of standard-of-care antibiotics and potential underestimation of severe baseline C. difficile infection, given many initial assessments were performed on patients already receiving antibiotics. Overall, this is a well-powered study with optimal follow-up that suggests neutralization of toxin B via bezlotoxumab may reduce disease recurrence.

Click to read the study, published today in NEJM

Relevant Reading: Recurrent Clostridium difficile infection: from colonization to cure

RELATED REPORTS

Multispecies probiotic reduces overall risk of diarrhea in antibiotic-treated children

Very-low-calorie diet leads to significant but reversible changes in gut microbiome

Wellness Check: Nutrition

In-Depth [randomized controlled trial]: In these nearly identical double-blind, randomized, placebo controlled trials conducted between 2011 and 2015, 2655 adults receiving standard-of-care antibiotics to prevent C. difficile infection were randomized to receive either bezlotoxumab (n = 781), bezlotoxumab and actoxumab (n = 773), actoxumab (n = 232) and placebo (n = 773). Of note, only the MODIFY I trial included a single-therapy actoxumab group – the second trial excluded it due to it’s demonstrated lack of efficacy. The primary end point was recurrent infection, defined as a new episode after initial clinical cure within 12 weeks after treatment infusion. In the MODIFY I trial, for the bezlotoxumab-only and placebo groups, recurrence rates were 17% (67 of 386) and 28% (109 of 395), respectively (95%CI 15.9 to -4.3; p < 0.001). Similarly, in the MODIFY II trial, for the bezlotoxumab-only and placebo groups, recurrence rates were 16% (62 of 395) and 26% (97 or 378), respectively (95%CI 17.4 to -5.9; p < 0.001). The bezlotoxumab and actoxumab combination groups were also more efficacious in reducing recurrence compared to placebo. Rates of adverse events were similar between groups, with the most common events being abdominal pain, diarrhea and nausea.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Clostridium difficile
Previous Post

No difference between therapeutic hypo- and normo-thermia with in-hospital cardiac arrest in children

Next Post

Swedish study shows better glycemic control with continuous glucose monitoring

RelatedReports

Probiotics improve colic, reduce GI disorders in infants
Gastroenterology

Multispecies probiotic reduces overall risk of diarrhea in antibiotic-treated children

July 13, 2022
Of Background Image
Gastroenterology

Very-low-calorie diet leads to significant but reversible changes in gut microbiome

July 27, 2021
Provision of medically-tailored meals linked with lower admissions and medical spending
Wellness

Wellness Check: Nutrition

July 22, 2021
Molecular testing for Clostridium difficile may not predict disease activity
Gastroenterology

Quick Take: Trends in diverting loop ileostomy vs. total abdominal colectomy as surgical management for Clostridium Difficile colitis

July 12, 2019
Next Post
AAP recommends disaster preparedness measures for children

Swedish study shows better glycemic control with continuous glucose monitoring

Pediatric DKA associated with recent acute care visits

Improved glycemic control with continuous glucose monitoring in American diabetics

Unenhanced magnetic resonance imaging highly sensitive and specific for acute appendicitis

External compression computed tomography may increase diagnostic accuracy in appendicitis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Daily disposable contact lenses may lower risk for Acanthamoeba keratitis
  • Vitamin D deficiency may be associated with sleep disorders in children
  • Prasinezumab therapy does not affect Parkinson’s Disease progression
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.